Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of the Anti-inflammatory Effects of Norflo Oro in Acute Relapses of HLA-B27 Associated Autoimmune Uveitis: a Multicenter Randomized, Placebo Controlled, Double-blind Clinical Study

NCT03584724 is registered in ClinicalTrials.gov with Eye Pharma as lead sponsor.

NCT NCT03584724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03584724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of the Anti-inflammatory Effects of Norflo Oro in Acute Relapses of HLA-B27 Associated Autoimmune Uveitis: a Multicenter Randomized, Placebo Controlled, Double-blind Clinical Study
Lead sponsor
Eye Pharma
Phase
Phase 1
Overall status
Completed
Start date
December 19, 2018
Completion date
December 30, 2020
Enrollment
49 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

uveitis